AARS2

Across TCGA pan-cancer cohorts, AARS2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AARS2 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher AARS2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated AARS2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

UCEC, LSCC, and PDAC are the cancer types where AARS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Quartile	II,III,IV	0.501	1.000	.025	12	view →
LSCC	DFS	Tertile	II,III,IV	1.000	0.850	.014	9	view →
PDAC	OS	Median	IV	0.836	0.491	.024	8	view →
CCRCC	DFS	Median	II,III,IV	0.595	0.814	.019	7	view →
HNSC	OS	Median	All	0.633	0.791	.034	4	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AARS2–UCEC (DFS)

Open the UCEC breakdown →